CO.DON: another important step towards European expansion

27.03.2017 | press release, Aktuell

Berlin / Teltow, 27 March 2017 - On its way towards European markets CO.DON AG has reached another important milestone: following a multi-stage selection process the UK Department of Health has appointed the National Institute for Health and Care Excellence (NICE) to carry out a single technology appraisal for the articular cartilage product from CO.DON AG.

This final round of appraisal for the articular cartilage product from CO.DON AG paves the way for the product to be funded by the public National Health Service.Approximately 88% of the UK population is covered by the NHS.

Whereas in Germany the assessment of pharmaceutical products is carried out by the Institute for Quality und Cost-effectiveness in the Healthcare System (IQWiG) and appraisal is the responsibility of the Joint Federal Committee (G-BA), the highest governance body in Germany's joint system of self-regulatory healthcare, the NICE combines both functions under one roof. In this capacity the institute also decides on funding for the treatments offered.

As part of the preparations for European market entry, the UK is an important reference market for funding arrangements in over 60 countries around the world.

About CO.DON AG:CO.DON AG develops, produces and markets in Germany autologous cell therapies for the minimally invasive repair of cartilage damage in joints following traumatic or degenerative defects. CO.DON condrosphere® is a cell therapy product that uses only the patient's own cartilage cells ('autologous chondrocytes'). CO.DON condrosphere® has been approved by the German federal agency PEI in accordance with Section 4b of the German Pharmaceuticals Act (AMG) and is currently undergoing Phase II and III clinical trials to obtain European marketing authorisation. CO.DON condrosphere® has been used for more than 10 years in over 120 clinics to treat more than 10,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007 and for the treatment of vertebral joints since 2008. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO).

Further information can be found at www.ihre-zellzuechter.deor www.codon.de

Investor Relations and Press Contact:

Matthias Meißner, M.A.

Corporate communications / IR / PR

Tel. +49 (0)30 240352330

Fax +49 (0)30 240352309

Email: ir@codon.de